1-(3-amino-1-ethyl-1H-pyrazol-4-yl)ethanone | 1269440-91-6

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 1-(3-amino-1-ethyl-1H-pyrazol-4-yl)ethanone
• 英文别名: 1-(3-amino-1-ethylpyrazol-4-yl)ethanone
• CAS: 1269440-91-6
• 化学式: C₇H₁₁N₃O
• 分子量: 153.184
• InChiKey: RAZYWQMDQSSKND-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.4
• 重原子数：
  11
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.43
• 拓扑面积：
  60.9
• 氢给体数：
  1
• 氢受体数：
  3

文献信息

• COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS
  申请人：Huang Shenlin

  公开号：US20110306625A1

  公开（公告）日：2011-12-15

  The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of B-Raf.

  本发明提供了一类新型化合物，包括这些化合物的药物组成物，以及使用这些化合物治疗或预防与异常或失调的激酶活性相关的疾病或疾病的方法，特别是涉及B-Raf异常活化的疾病或疾病的方法。
• Compounds and compositions as protein kinase inhibitors
  申请人：Array BioPharma, Inc.

  公开号：US10005761B2

  公开（公告）日：2018-06-26

  The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of B-Raf.

  本发明提供了一类新型化合物、包含此类化合物的药物组合物以及使用此类化合物治疗或预防与激酶活性异常或失调有关的疾病或紊乱的方法，特别是涉及 B-Raf 异常活化的疾病或紊乱。
• EP2727918A1
  申请人：——

  公开号：EP2727918A1

  公开（公告）日：2014-05-07
• Compounds and Compositions as Protein Kinase Inhibitors
  申请人：Array Biopharma Inc.

  公开号：EP2727918B1

  公开（公告）日：2016-10-12
• BENZODIAZEPINE DERIVATIVES AS RSV INHIBITORS
  申请人：Enanta Pharmaceuticals, Inc.

  公开号：US20170022221A1

  公开（公告）日：2017-01-26

  The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit Respiratory Syncytial Virus (RSV). The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from RSV infection. The invention also relates to methods of treating an RSV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.